Cross-sectional epidemiological studies in humans have shown that low serum adiponectin is associated with insulin resistance, obesity, dyslipidemia, coronary artery disease, hypertension or type 2 diabetes (T2D) [4]–[8]. Here, ADIPOQ is linked to metabolic syndrome.